Adult patients with Prader-Willi syndrome:: clinical characteristics, life circumstances and growth hormone secretion

被引:34
作者
Partsch, CJ
Lämmer, C
Gillessen-Kaesbach, G
Pankau, R
机构
[1] Univ Kiel, Dept Paediat, D-24105 Kiel, Germany
[2] Childrens Hosp St Bernward, Hildesheim, Germany
[3] Univ Essen Gesamthsch, Inst Human Genet, Essen, Germany
关键词
growth hormone-releasing hormone-arginine test; morbidity; obesity; short stature; sleep apnoea;
D O I
10.1016/S1096-6374(00)80015-5
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Prader-Willi syndrome is characterized by a typical clinical phenotype and by a complex genetic basis that includes large deletions, uniparental disomy and imprinting mutations of chromosome region 15q11-q13. This report delineates the clinical characteristics, morbidity and growth hormone secretory status of 19 adults with Prader-Willi syndrome, The patients were 18-34 years of age. Morbidity included marked obesity with body mass index in excess of 30 kg/m(2) (grade 1-3 according to WHO), metabolic diseases, sleep apnoea and lipolymphoedema. Severe growth hormone deficiency (GHD) was seen in 38% of the patients, and levels of insulin-like growth factor I were decreased in 87%. Thus, GHD is seen, not only in children with Prader-Willi syndrome, but also in adults with the syndrome. (C) 2000 Harcourt Publishers Ltd.
引用
收藏
页码:81 / 85
页数:5
相关论文
共 28 条
[1]   Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone plus arginine as provocative tests for the diagnosis of GH deficiency in adults [J].
Aimaretti, G ;
Corneli, G ;
Razzore, P ;
Bellone, S ;
Baffoni, C ;
Arvat, E ;
Camanni, F ;
Ghigo, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) :1615-1618
[2]  
Angulo M, 1996, J PEDIATR ENDOCR MET, V9, P393
[3]  
ANGULO M, 1991, Journal of Pediatric Endocrinology, V4, P167
[4]  
Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379
[5]   Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study [J].
Carrel, AL ;
Myers, SE ;
Whitman, BY ;
Allen, DB .
JOURNAL OF PEDIATRICS, 1999, 134 (02) :215-221
[6]   GROWTH-HORMONE SECRETION IN PRADER-WILLI SYNDROME [J].
COSTEFF, H ;
HOLM, VA ;
RUVALCABA, R ;
SHAVER, J .
ACTA PAEDIATRICA SCANDINAVICA, 1990, 79 (11) :1059-1062
[7]   Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome [J].
Davies, PSW ;
Evans, S ;
Broomhead, S ;
Clough, H ;
Day, JME ;
Laidlaw, A ;
Barnes, ND .
ARCHIVES OF DISEASE IN CHILDHOOD, 1998, 78 (05) :474-476
[8]   Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance [J].
Eiholzer, U ;
Gisin, R ;
Weinmann, C ;
Kriemler, S ;
Steinert, H ;
Torresani, T ;
Zachmann, M ;
Prader, A .
EUROPEAN JOURNAL OF PEDIATRICS, 1998, 157 (05) :368-377
[9]   Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome [J].
Eiholzer, U ;
Stutz, K ;
Weinmann, C ;
Torresani, T ;
Molinari, L ;
Prader, A .
EUROPEAN JOURNAL OF PEDIATRICS, 1998, 157 (11) :890-893
[10]  
FESSELER WH, 1983, MONATSSCHR KINDERH, V131, P844